17634459

Source:http://linkedlifedata.com/resource/pubmed/id/17634459

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0010346, umls-concept:C0677908, umls-concept:C1872109
pubmed:issue	3
pubmed:dateCreated	2007-7-19
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00152425
pubmed:abstractText	Certolizumab pegol is a pegylated humanized Fab' fragment with a high binding affinity for tumor necrosis factor alpha that does not induce apoptosis of T cells or monocytes.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/17634459, http://linkedlifedata.com/resource/pubmed/commentcorrection/17634459-17634466, http://linkedlifedata.com/resource/pubmed/commentcorrection/17634459-18095318
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0255562
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Antinuclear, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/C-Reactive Protein, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Fab Fragments, http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha, http://linkedlifedata.com/resource/pubmed/chemical/certolizumab pegol
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	1533-4406
pubmed:author	pubmed-author:BloomfieldRalphR, pubmed-author:HanauerStephen BSB, pubmed-author:Khaliq-KareemiManiM, pubmed-author:LawranceIan CIC, pubmed-author:McColmJulietJ, pubmed-author:PRECISE 2 Study Investigators, pubmed-author:SandbornWilliam JWJ, pubmed-author:SchreiberStefanS, pubmed-author:ThomsenOle ØstergaardOØ
pubmed:copyrightInfo	Copyright 2007 Massachusetts Medical Society.
pubmed:issnType	Electronic
pubmed:day	19
pubmed:volume	357
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	239-50
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:17634459-Adolescent, pubmed-meshheading:17634459-Adult, pubmed-meshheading:17634459-Aged, pubmed-meshheading:17634459-Anti-Inflammatory Agents, pubmed-meshheading:17634459-Antibodies, pubmed-meshheading:17634459-Antibodies, Antinuclear, pubmed-meshheading:17634459-Antibodies, Monoclonal, Humanized, pubmed-meshheading:17634459-C-Reactive Protein, pubmed-meshheading:17634459-Crohn Disease, pubmed-meshheading:17634459-Double-Blind Method, pubmed-meshheading:17634459-Drug Therapy, Combination, pubmed-meshheading:17634459-Female, pubmed-meshheading:17634459-Follow-Up Studies, pubmed-meshheading:17634459-Humans, pubmed-meshheading:17634459-Immunoglobulin Fab Fragments, pubmed-meshheading:17634459-Immunosuppressive Agents, pubmed-meshheading:17634459-Injections, Subcutaneous, pubmed-meshheading:17634459-Male, pubmed-meshheading:17634459-Middle Aged, pubmed-meshheading:17634459-Polyethylene Glycols, pubmed-meshheading:17634459-Remission Induction, pubmed-meshheading:17634459-Treatment Outcome, pubmed-meshheading:17634459-Tumor Necrosis Factor-alpha
pubmed:year	2007
pubmed:articleTitle	Maintenance therapy with certolizumab pegol for Crohn's disease.
pubmed:affiliation	Hospital for General Internal Medicine, Christian Albrechts University, Kiel, Germany. s.schreiber@mucosa.de
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study